



Differences between cultured astrocytes from neonatal and adult Wistar rats: focus on in vitro aging experimental models

Fernanda Becker Weber¹ · Camila Leite Santos¹ · Amanda da Silva¹ · Izaviany Schmitz¹ · Ester Rezena¹ · Carlos-Alberto Gonçalves^{1,2,3} · André Quincozes-Santos^{1,2,3} · Larissa Daniele Bobermin^{1,2}

Received: 19 September 2023 / Accepted: 7 March 2024 / Published online: 28 March 2024 / Editor: Tetsuji Okamoto
© The Society for In Vitro Biology 2024

Abstract

Astrocytes play key roles regulating brain homeostasis and accumulating evidence has suggested that glia are the first cells that undergo functional changes with aging, which can lead to a decline in brain function. In this context, in vitro models are relevant tools for studying aged astrocytes and, here, we investigated functional and molecular changes in cultured astrocytes obtained from neonatal or adult animals submitted to an in vitro model of aging by an additional period of cultivation of cells after confluence. In vitro aging induced different metabolic effects regarding glucose and glutamate uptake, as well as glutamine synthetase activity, in astrocytes obtained from adult animals compared to those obtained from neonatal animals. In vitro aging also modulated glutathione-related antioxidant defenses and increased reactive oxygen species and cytokine release especially in astrocytes from adult animals. Interestingly, in vitro aged astrocytes from adult animals exposed to pro-oxidant, inflammatory, and antioxidant stimuli showed enhanced oxidative and inflammatory responses. Moreover, these functional changes were correlated with the expression of the senescence marker p21, cytoskeleton markers, glutamate transporters, inflammatory mediators, and signaling pathways such as nuclear factor κ B (NF κ B)/nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1). Alterations in these genes are remarkably associated with a potential neurotoxic astrocyte phenotype. Therefore, considering the experimental limitations due to the need for long-term maintenance of the animals for studying aging, astrocyte cultures obtained from adult animals further aged in vitro can provide an improved experimental model for understanding the mechanisms associated with aging-related astrocyte dysfunction.

Keywords Aging · Glutamate homeostasis · Inflammatory response · In vitro astrocytes · Oxidative stress

Introduction

Astrocytes comprise the most abundant glial subtype and are involved in a variety of physiological functions, thus playing a critical role for the central nervous system (CNS)

homeostasis (Verkhatsky and Nedergaard 2018). They regulate synaptic function and plasticity, maintain glutamate neurotransmitter homeostasis, and provide metabolic, antioxidant, and neurotrophic support (Verkhatsky and Nedergaard 2018; Liu *et al.* 2023). In addition, astrocytes can respond to protective and/or injury stimuli by triggering several signaling pathways, including nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1), nuclear factor κ B (NF κ B), mitogen activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)/Akt, which may result in both defense and pathological processes (Quincozes-Santos *et al.* 2021).

In this regard, dysfunctional astrocytes and the loss of their protective capacity have been closely related to neuropathologies, including age-related and neurodegenerative diseases (Palmer and Ousman 2018; Lau *et al.* 2023). In fact, aging has been associated with substantial changes of astrocyte functionality and with changes in

✉ Larissa Daniele Bobermin
larissabobermin@gmail.com

¹ Programa de Pós-Graduação Em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil

² Programa de Pós-Graduação Em Neurociências, Instituto de Ciências Básicas da Saúde, Universidade Federal Do Rio Grande Do Sul, Ramiro Barcelos, 2600, Porto Alegre, RS 90035-003, Brazil

³ Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil

the expression of senescence markers, including p21. A common event underlying aging is a low-grade inflammatory response, which has been referred as inflammaging (Franceschi *et al.* 2018). In this context, astrocytes are an important source of pro-inflammatory mediators in the CNS and their chronic production, along with increased reactive oxygen/nitrogen species (ROS/RNS), may have detrimental effects on neighboring cells (Guerrero *et al.* 2021).

Previous studies from our group have shown that primary astrocyte cultures obtained from animals of different ages are a useful model to study the age-related functional changes of astrocytes and their underlying molecular mechanisms (Souza *et al.* 2013; Bellaver *et al.* 2017; Santos *et al.* 2018; Bobermin *et al.* 2022; Leite Santos *et al.* 2023; Sovrani *et al.* 2023). However, it is important to consider experimental limitations due to the need for long-term maintenance of the animals. Therefore, considering the relevance of understanding the mechanisms involved in cellular alterations of astrocytes during the aging process, the *in vitro* model of aging astrocytes (continuous cultivation of cells after confluence) may be an additional and important tool (Gottfried *et al.* 2002; Pertusa *et al.* 2007; Souza *et al.* 2015; Matias *et al.* 2022, 2023). In this regard, since aging phenotypes may already appear in middle aged rodents (Souza *et al.* 2013; Bellaver *et al.* 2017; Yanai and Endo 2021), the utilization of astrocyte cultures obtained from mature animals for further *in vitro* aging can provide an improved experimental model.

In this study, we investigated functional and neurochemical changes in astrocytes from neonatal and adult Wistar rats aged *in vitro*. We functionally characterized astrocytes by evaluating glucose and glutamate uptake, glutamine synthetase (GS) activity, ROS/RNS production, antioxidant defenses, inflammatory response, and the expression of genes associated with these processes. In addition, we evaluated the response of the cells to oxidative, inflammatory, and protective stimuli by using hydrogen peroxide (H₂O₂), lipopolysaccharide (LPS), and resveratrol, respectively, as well as the participation of PI3K, p38 MAPK, HO-1 and Toll-like receptor 4 (TLR4) in the mechanisms of these effects.


Materials and methods

Animals Male Wistar rats (1–2 and 90 old) were obtained from the breeding colony of Department of Biochemistry (UFRGS, Porto Alegre, Brazil), maintained under controlled environment (12 h light/12 h dark cycle; 22 ± 1 °C; ad libitum access to food and water). All animal experiments were performed in accordance with the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Federal University of Rio Grande do Sul Animal Care and Use Committee (process number: 37665).

Primary astrocyte cultures Neonate (1–2 old) and adult (90 old) Wistar rats had their cortices aseptically dissected from cerebral hemispheres, followed by meninges removal. The tissues were digested in Hank's balanced salt solution (HBSS) containing 0.003% DNase using trypsin (0.05%) and papain (40 U/mL), as previously described (Souza *et al.* 2013; Bobermin *et al.* 2020). After mechanical dissociation and centrifugation, the cells were resuspended in DMEM/F12 [10% fetal bovine serum (FBS), 15 mM HEPES, 14.3 mM NaHCO₃, 2.5 µg/mL Fungizone and 0.05 mg/mL gentamicin; Gibco, Grand Islands, NY], plated on 6- or 24-well plates pre-coated with poly-L-lysine at a density of 3–5 × 10⁵ cells/cm². Astrocytes were cultured at 37 °C in a 5% CO₂ incubator. During the first week, the culture medium was replaced once every two, and from the second week on, it was replaced once every four when astrocytes received medium supplemented with 20% FBS until they reached confluence (at approximately 21 *in vitro* – DIV).

In vitro aging For the experimental *in vitro* model of aging, astrocyte cultures from both neonate and adult animals were maintained for additional 21 *in vitro* (DIV) after reaching confluence, when the experiments were performed (Fig. 1). Therefore, control astrocytes were maintained in culture for 21 days (21 DIV) while *in vitro* aged astrocytes maintained for 42 (42 DIV). Primary astrocyte cultures were alternatively subjected to oxidative or inflammatory challenges with H₂O₂ (100 µM for 3 h) and LPS (10 µg/ml for 3 h) or incubated with the antioxidant resveratrol (100 µM for 3 h). Pharmacological

Figure 1. *In vitro* aging experimental design. Astrocytes obtained from neonate and adult animals were cultured until reach the confluence (at approximately 21 DIV – control condition) or they were maintained for additional 21 *in vitro* (totalizing 42 DIV – *in vitro* aging model).



inhibitors for PI3K (LY294002, 10 μM for 3 h), p38 MAPK (SB203580, 5 μM for 3 h), HO-1 (ZnPP IX, 10 μM for 3 h) and TLR4 (CLI-095, 5 μM for 3 h) were also used as indicated, according with our previous studies (Quincozes-Santos *et al.* 2013, 2014; Souza *et al.* 2013; Bellaver *et al.* 2015; Rosa *et al.* 2018).

MTT reduction assay MTT (methylthiazolyldiphenyl-tetrazolium bromide; Sigma-Aldrich, St. Louis, MO) was added to the medium at a concentration of 50 $\mu\text{g}/\text{mL}$ and cells were incubated for 3 h at 37 $^{\circ}\text{C}$ in an atmosphere of 5% CO_2 . Subsequently, the medium was removed and the MTT crystals were dissolved in dimethyl-sulfoxide. Absorbance values were measured at 560 nm and 650 nm (Bobermin *et al.* 2020). The results are expressed as percentages relative to the control conditions.

Glucose uptake Glucose uptake was assessed as previously described using 2-Deoxy-D-[1,2- ^3H]-glucose ([^3H]-2DG; Amersham, Buckinghamshire, UK) (Souza *et al.* 2013). Briefly, the cell medium was replaced with fresh DMEM/F12 1% FBS for 2 h at 37 $^{\circ}\text{C}$. Astrocytes were incubated with DMEM/F12 1% FBS containing 1 mCi/ml [^3H]-2DG for 20 min at 37 $^{\circ}\text{C}$. After incubation, the cells were rinsed with HBSS and lysed overnight with NaOH 0.3 M. The incorporated radioactivity was measured in a scintillation counter. Cytochalasin B (10 mM) was used as a specific glucose transporter inhibitor. Glucose uptake was determined by subtracting the uptake in the presence of cytochalasin B from the total uptake.

Glutamate uptake The glutamate uptake was performed as previously described (Souza *et al.* 2013). Briefly, the cells were incubated at 37 $^{\circ}\text{C}$ in Hank's balanced salt solution (HBSS) containing the following components (in mM): 137 NaCl, 5.36 KCl, 1.26 CaCl_2 , 0.41 MgSO_4 , 0.49 MgCl_2 , 0.63 Na_2HPO_4 , 0.44 KH_2PO_4 , 4.17 NaHCO_3 , and 5.6 glucose, adjusted to pH 7.4. The assay was started by the addition of 0.1 mM L-glutamate and 0.33 $\mu\text{Ci}/\text{ml}$ L-[2,3- ^3H] glutamate (Amersham, Buckinghamshire, UK). The incubation was stopped after 7 min by removal of the medium and rinsing twice the cells with ice-cold HBSS. The cells were then lysed in a solution containing 0.5 M NaOH. Incorporated radioactivity was measured in a scintillation counter. Sodium-independent uptake was determined using ice-cold N-methyl-D-glucamine instead of sodium chloride. Sodium-dependent glutamate uptake was obtained by subtracting the sodium-independent uptake from the total uptake.

Glutamine synthetase activity The activity of GS was determined as previously described (dos Santos *et al.* 2006; Kleinkauf-Rocha *et al.* 2013). Briefly, the cell homogenate was added to a reaction mixture containing 10 mM MgCl_2 ,

50 mM L-glutamate, 100 mM imidazole-HCl buffer (pH 7.4), 10 mM 2-mercaptoethanol, 50 mM hydroxylamine-HCl. The addition of 10 mM ATP started the reaction, which was continued for 15 min at 37 $^{\circ}\text{C}$. A solution containing 370 mM ferric chloride, 670 mM HCl and 200 mM trichloroacetic acid was then added to stop the reaction. After centrifugation, the absorbance of the supernatant was measured at 530 nm. A calibration curve was prepared using γ -glutamyl hydroxamate (Sigma-Aldrich) and treated with ferric chloride reagent. The results are expressed in $\mu\text{mol}/\text{mg}$ protein/h.

Glutathione levels Intracellular levels of glutathione (GSH) were assessed in cell lysates suspended in a sodium phosphate (100 mM)/KCl (140 mM) buffer, pH 8.0, containing 5 mM EDTA. Protein was precipitated with 1.7% meta-phosphoric acid, followed by centrifugation. The supernatant was then incubated with o-phthaldialdehyde (Sigma-Aldrich, at a concentration of 1 mg/ml methanol) at 22 $^{\circ}\text{C}$ for 15 min (Browne and Armstrong 1998). A calibration curve (GSH solutions from 0 to 500 μM ; Sigma-Aldrich) was performed and fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively. The results are expressed in nmol/mg protein.

Glutamate cysteine ligase activity Glutamate cysteine ligase (GCL) was assayed according to Seelig *et al.*, with slight modifications (Seelig and Meister 1985). Cell lysate, suspended in a sodium phosphate buffer containing 140 mM KCl, was diluted with 100 mM sodium phosphate buffer (pH 8.0) containing 5 mM EDTA. The enzyme activity was determined after monitoring the NADH oxidation at 340 nm in sodium phosphate/KCl (pH 8.0) containing 5 mM ATP- Na_2 , 2 mM phosphoenolpyruvate, 10 mM L-glutamate, 10 mM L- α -amino-buturate, 20 mM MgCl_2 , 2 mM EDTA- Na_2 , 0.2 mM NADH, and 17 μg of pyruvate kinase/lactate dehydrogenase. The results are expressed in nmol/mg protein/min.

Glutathione peroxidase activity Glutathione peroxidase (GPx) activity was measured using the RANSEL kit from Randox (Autrim, UK). The concentration of GPx in lysed cells is assessed by measuring the absorption of NADPH at 340 nm. The results are expressed as U/mg protein.

DCFH oxidation Intracellular ROS levels were detected using 2'-7'-dichlorofluorescein diacetate (DCFH-DA; Sigma-Aldrich), which was added to the culture medium at a concentration of 10 μM and incubated for 30 min at 37 $^{\circ}\text{C}$. The intensity of fluorescence was measured in a plate reader with excitation at 485 nm and emission at 520 nm (Bobermin *et al.* 2022). The results are expressed as percentages relative to the control conditions.

ELISA assays The extracellular levels of the cytokines tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and interleukin-10 (IL-10), as well as of the trophic factor GDNF, were measured in the culture medium of astrocytes using ELISA commercial kits. The assay ranges for the kits are the following: 16 to 2000 pg/ml for TNF- α (Invitrogen, Waltham MA catalog #88–7340–22); 31.3 to 2000 pg/ml for IL-1 β (Invitrogen, catalog #BMS630); 31.3 to 2000 pg/ml for IL-6 (Invitrogen, catalog #BMS625); 15.6 to 1000 pg/ml for IL-10 (Invitrogen, catalog #BMS629); 31.2 to 2000 pg/ml for GDNF (Abcam; Cambridge, UK catalog #ab213901). The results are expressed in pg/ml.

RNA extraction and quantitative RT-PCR Total RNA was isolated from astrocyte cultures using TRIzol Reagent (Invitrogen). The concentration and purity of the RNA were determined spectrophotometrically at a ratio of 260:280. Then, 1 μ g of total RNA was reverse transcribed using Applied Biosystems High Capacity complementary DNA (cDNA) Reverse Transcription Kit (Applied Biosystems, Waltham, MA) in a 20 μ L reaction according to manufacturer's instructions. The messenger RNA (mRNA) encoding each target genes was quantified using the TaqMan real-time RT-PCR system with inventory primers and probes purchased from Applied Biosystems as summarized in Table 1. Quantitative RT-PCR was performed using the StepOne System from Applied Biosystems during 40 cycles of amplification. Target mRNA levels were normalized to β -actin levels. Results were analyzed employing the $2^{-\Delta\Delta C_t}$ method (Livak and Schmittgen 2001).

Table 1. Genes analyzed by quantitative RT-PCR (qRT-PCR)

mRNA target	Assay ID
Aquaporin 4 (AQP4)	Rn00563196_m1
β -actin	Rn00667869_m1
Cyclooxygenase-2 (COX-2)	Rn01483828_m1
Glial fibrillary acidic protein (GFAP)	Rn00566603_m1
Glutamate aspartate transporter (GLAST)	Rn00570130_m1
Glutamate transporter 1 (GLT-1)	Rn00691548_m1
Glutamine synthetase (GS)	Rn01483107_m1
Heme oxygenase-1 (HO-1)	Rn01536933_m1
Inducible nitric oxide synthase (iNOS)	Rn00561646_m1
Interleukin-1 β (IL-1 β)	Rn00580432_m1
Nestin	Rn00564394_m1
Nuclear factor erythroid 2-related factor 2 (Nrf2)	Rn00582415_m1
Nuclear factor kappa B p65 subunit (NF κ B p65)	Rn01502266_m1
p21	Rn00589996_m1
Tumor necrosis factor- α (TNF- α)	Rn99999017_m1
Vimentin	Rn00667825_m1

Protein assay Protein content was measured using Lowry's method with bovine serum albumin as a standard (Lowry *et al.* 1951).

Statistical analyses Differences among groups were statistically analyzed using two-way analysis of variance (ANOVA) followed by Tukey's test or Student's t test. All analyses were performed using the GraphPad Prism 9 (GraphPad Software, Inc., La Jolla, CA). Values of $P < 0.05$ were considered significant; * refers to statistically significant differences between control and aged in vitro astrocytes (same age) and # refers to statistically significant differences between ages (astrocytes from neonatal *versus* adult animals).

Results

Astrocytes from neonatal and adult animals aged in vitro showed glial functional changes In vitro aging (astrocytes cultured for 42 days) did not affect the cell viability of primary astrocyte cultures obtained from both neonatal and adult animals compared to control conditions (21 days in vitro; data not shown). However, in vitro aging reduced glucose uptake, but only in astrocytes from neonatal animals (Fig. 2A; $P = 0.0003$). At control conditions, glucose uptake is decreased in astrocytes from adult animals compared to astrocytes from neonates ($P = 0.0017$). Regarding glutamate uptake, at control conditions, glutamate uptake was also decreased in astrocytes from adult animals compared to those obtained from neonates (Fig. 2B; $P < 0.0001$). In vitro aging produced opposite effects; in astrocytes derived from neonatal rats, glutamate uptake was increased ($P < 0.0001$), while in astrocytes obtained from adults it was decreased ($P = 0.0065$). To investigate the involvement of PI3K and p38 MAPK signaling in the changes in glutamate uptake induced by in vitro aging, we incubated astrocytes with LY294002 and SB203580 inhibitors. Inhibition of PI3K pathway prevented the effect of in vitro aging on glutamate uptake in neonatal astrocytes (table insert, Fig. 2B). In contrast, p38 MAPK inhibition prevented the impairment of glutamate uptake in adult astrocytes aged in vitro (table insert, Fig. 2B). In neonatal astrocytes, in vitro aging did not change the activity of GS, but it was decreased in adult astrocytes (Fig. 2C; $P < 0.0001$). Comparing control neonatal and adult astrocytes, the activity of GS was decreased in the cultures obtained from adult animals ($P = 0.0001$).

In vitro aging affected redox homeostasis in astrocytes GSH content was markedly decreased by in vitro aging in astrocytes obtained from adult animals ($P = 0.0017$), but not from neonates (Fig. 3A). There was also an age-dependent decrease of GSH levels at control conditions ($P < 0.0001$). In agreement with that, the activity of GCL (Fig. 3B)




Figure 2. Effects of in vitro aging on glucose and glutamate uptake and GS activity in astrocytes obtained from neonatal and adult animals. Astrocyte cultures obtained from neonatal and adult animals were cultured for 21 (control) or 42 (in vitro aging). Glucose uptake (A), glutamate uptake (B), and GS activity (C) were evaluated. Additionally, astrocytes were incubated with LY294002 (10 μ M) or SB203580 (5 μ M) for 3 h to examine the modulatory roles of PI3K and p38 MAPK, respectively, on glutamate uptake (insert table). Data are presented as mean \pm S.D. and differences among groups were statistically analyzed using two-way analysis of variance (ANOVA), followed by Tukey's test ($n=6$ independent cultures and, at least, duplicate of treatments). Values of $P < 0.05$ were considered significant. * refers to statistically significant differences between control and aged in vitro astrocytes (same age) and # refers to statistically significant differences between ages (astrocytes from neonatal versus adult animals).

was decreased in astrocytes derived from adults, both upon in vitro aging ($P=0.0034$) and at control conditions ($P < 0.0001$). However, the activity of GPx was increased in astrocytes from adults aged in vitro ($P=0.0008$), as well as it was increased at basal conditions relative to astrocytes obtained from neonatal animals (Fig. 3C; $P=0.0001$).

In vitro aging also increased ROS production in both astrocytes obtained from neonatal and adult rats (Fig. 3D; $P=0.0033$ and $P < 0.0001$, respectively). An age-dependent increase of ROS production was also observed at control conditions ($P < 0.0001$). Astrocytes aged in vitro were then oxidatively challenged with H_2O_2 , which further increased ROS production in astrocytes from adult rats ($P < 0.0001$), but not in astrocytes from neonatal rats (Fig. 3E).

Astrocytes aged in vitro were also incubated with the antioxidant resveratrol, including in the presence of the inhibitor of HO-1 (ZnPP IX), which has been described as an important mediator of its protective effects. Resveratrol decreased ROS production in astrocytes derived from neonatal and adult animals and aged in vitro ($P < 0.0001$), but not in the presence of HO-1 inhibitor (Fig. 3F).

In vitro aging induced changes in inflammatory response and GDNF release in astrocytes Oxidative stress and inflammatory responses are tightly linked processes. Astrocytes aged in vitro released increased amounts of TNF- α compared to their respective controls, with a greater effect observed in astrocytes from adult rats (Fig. 4A; $P=0.0053$ and $P < 0.0001$). The extracellular levels of this cytokine were also increased between ages at control conditions ($P=0.0044$). LPS challenge potentiated the release of TNF- α only in astrocytes from adult rats aged in vitro (Fig. 4B; $P < 0.0001$). Moreover, incubation with TLR4 inhibitor prevented TNF- α release induced by LPS (Fig. 4B). When aged astrocytes were incubated with resveratrol, an HO-1-dependent decrease of TNF- α ($P < 0.0001$) was observed only in astrocytes obtained from adult animals (Fig. 4C).

In vitro aging also increased the release of IL-1 β (Fig. 4D $P < 0.0001$), which was further increased by LPS, in both astrocytes obtained from neonatal ($P=0.0001$) and adult ($P < 0.0001$) animals. Of note, LPS challenge induce an increase in IL-1 β release three-fold higher than in astrocytes from neonatal rats. At control conditions, extracellular levels of IL-1 β were also augmented comparing astrocyte cultures obtained from both ages ($P < 0.0001$).

After characterizing the effects of in vitro aging in neonatal and adult astrocytes relative to control conditions, the subsequent analyses were performed comparing only astrocytes aged in vitro from both ages. The extracellular levels of IL-6 were higher in in vitro aged astrocytes from adult animals compared to those obtained from neonatal animals (Fig. 4E; $P < 0.001$). However, the extracellular levels of




Figure 3. Effects of in vitro aging on astrocyte redox homeostasis. Astrocyte cultures obtained from neonatal and adult animals were cultured for 21 days (control) or 42 days (in vitro aging). GSH content (A), GCL activity (B), GPx activity (C), and ROS production (D–F) were evaluated. Additionally, astrocytes were incubated with H_2O_2 (100 μ M), resveratrol (100 μ M) or HO-1 inhibitor (10 μ M) for 3 h to assess ROS production. Data are presented as mean \pm S.D. and differences among groups were statistically analyzed using two-way analysis of variance (ANOVA), followed by Tukey's test ($n=6$ independent cultures and, at least, duplicate of treatments). Values of $P < 0.05$ were considered significant. * refers to statistically significant differences between control and aged in vitro astrocytes (same age) and # refers to statistically significant differences between ages (astrocytes from neonatal versus adult animals).

the anti-inflammatory cytokine IL-10 and the trophic factor GDNF were decreased in astrocytes aged in vitro derived from adult rats compared to neonatal rats (Fig. 4F and G, respectively, $P < 0.001$).

Astrocytes from adult animals aged in vitro showed differences in the expression of key genes compared to astrocytes from neonatal animals aged in vitro We then compared the expression of genes involved in key astrocyte functions between astrocytes isolated from neonatal and adult rats aged in vitro. The expression of senescence marker p21 was increased in astrocytes from adults aged in vitro (Fig. 5A; $P < 0.001$). However, the mRNA levels of cytoskeleton proteins GFAP (Fig. 5B; $P < 0.001$), vimentin (Fig. 5C; $P = 0.005$), and nestin (Fig. 5D; $P = 0.005$) were decreased. Glutamate transporters GLAST and GLT-1 were also markedly downregulated (Fig. 5E and F, respectively, $P < 0.001$), while the expression of GS did not change (Fig. 5G) and the mRNA levels of AQP4 increased (Fig. 5H; $P < 0.001$). The expressions of inflammatory genes TNF- α (Fig. 5J), IL-1 β (Fig. 5J), COX-2 (Fig. 5K), and iNOS (Fig. 5L), as well as of the p65 NF κ B (Fig. 5M), were increased in astrocytes

obtained from adult animals aged in vitro compared to astrocytes from neonatal animals aged in vitro ($P < 0.001$). In contrast, mRNA levels of cytoprotective molecules Nrf2 (Fig. 5N) and HO-1 (Fig. 5O) were decreased ($P < 0.001$).

Discussion

Recent evidence suggests that glia are the first cells that undergo a functional and neurochemical remodeling with aging, which may be tightly linked to an impaired protective capacity (Soreq *et al.* 2017; Clarke *et al.* 2018). Cultured astrocytes have been a widely used experimental approach to study aging-related changes in astrocyte functions, but since they are commonly isolated from newborn rodents, they are not exposed to challenging experiences throughout life and during aging process. In this regard, our group has demonstrated that primary astrocyte cultures obtained from adult and aged animals (90 to 2 old) can more reliably reproduce the alterations of glial functionality observed in aging (Bellaver *et al.* 2017; Santos *et al.* 2018; Bobermin *et al.* 2022; Sovrani *et al.* 2023), but it is important to consider the need for long-term maintenance of animals. Thus, the




Figure 4. In vitro aging changed the release of cytokines and GDNF. Astrocyte cultures obtained from neonatal and adult animals were cultured for 21 (control) or 42 (in vitro aging). Extracellular levels of TNF- α (A-C), IL-1 β (D), IL-6 (E), IL-10 (F) and GDNF (G) were measured. Additionally, astrocytes were incubated with LPS (100 μ M), TLR4 inhibitor, resveratrol (100 μ M) or HO-1 inhibitor (10 μ M) for 3 h to assess TNF- α or IL-1 β release. Data are presented as mean \pm S.D. and differences among groups were statistically analyzed

using two-way analysis of variance (ANOVA), followed by Tukey's test ($n=6$ independent cultures and, at least, duplicate of treatments). Values of $P < 0.05$ were considered significant. * refers to statistically significant differences between control and aged in vitro astrocytes (same age); ** refers to statistically significant differences between aged in vitro astrocytes without LPS and with LPS (same age); and # refers to statistically significant differences between ages (astrocytes from neonatal versus adult animals).


establishment of other in vitro models of aging is relevant to study the underlying mechanisms related to the transition from functional to potentially dysfunctional astrocytes. Astrocytes maintained in vitro after confluence (long-term astrocyte culture models) can show features of cellular senescence (Pertusa *et al.* 2007; Matias *et al.* 2022). Of note, the expression of p21 is a well-established senescence marker and its upregulation has been observed in astrocytes obtained from aged animals (Bellaver *et al.* 2017; Bobermin *et al.* 2022; Sovrani *et al.* 2023). Here, we found that in vitro aged astrocytes obtained from adult animals showed a markedly upregulation of p21 compared to in vitro aged astrocytes obtained from neonatal animals, thus they represent an advantage in culture methods for studying aged astrocytes. Moreover, other different cellular and molecular effects in astrocytes derived from neonatal and adult animals were observed, mainly regarding to glutamatergic, oxidative, and inflammatory parameters, which are commonly associated age-related brain diseases (Mattson and Arumugam 2018; Salas *et al.* 2020).

Hypometabolism has been observed during brain aging (Cunnane *et al.* 2020; Zhang *et al.* 2021) with implications in glial-to-neurons metabolic support. Of note, in addition to energy supply, glucose metabolism is important for maintaining brain redox homeostasis through NADPH generation by the pentose-phosphate pathway (Gonçalves *et al.*

2018). Aging can drive metabolic dysfunctions and affect the metabolic machinery of astrocytes (Chen *et al.* 2023). In this regard, glucose uptake activity affects the capacity of glycolysis, and it was observed a decrease in glucose uptake only in astrocytes aged in vitro obtained from neonatal animals. Metabolic alterations have also been observed in other in vitro models of aging in astrocytes, including a decrease in glucose transporter (GLUT-1) expression, which is essential for the entry of glucose into the CNS and is present in astrocytes (Cao *et al.* 2019). However, it is important to note that astrocytes of adult animals showed a decreased glucose uptake compared to cells from neonatal rats at control conditions, indicating that changes in astrocyte metabolism may precede aging.

Accumulated evidence has also demonstrated the relationship between astrocyte aging and glutamatergic system (Potier *et al.* 2010; Limbad *et al.* 2020). Astrocytes are responsible for the uptake of extracellular glutamate due to their high-affinity glutamate transporters, GLAST and GLT-1 (Danbolt 2001). Reinforcing the age-related effects on glutamate homeostasis, we observed that astrocytes from adult rats have a decreased glutamate uptake activity compared with astrocytes from neonatal rats at basal conditions. The in vitro model of aging caused opposite effects on glutamate uptake in astrocytes obtained from neonatal and adult rats. In agreement with previous findings (Gottfried *et al.*

Figure 5. In vitro aging changes the expression of genes involved in key astrocyte functions. Astrocyte cultures obtained from neonatal and adult animals were cultured for 42 (in vitro aging). The mRNA expression of p21 (A), GFAP (B), vimentin (C), nestin (D), GLAST (E), GLT-1 (F), GS (G), AQP4 (H), TNF- α (I), IL-1 β (J), COX-2 (K), iNOS (L), p65 NF κ B (M), Nrf2 (N), and HO-1 (O). Data are presented as mean \pm S.D. and differences among groups were statistically analyzed using Student's t test (n = 6 independent cultures and, at least, duplicate of treatments). Values of $P < 0.05$ were considered significant. # refers to statistically significant differences between ages (astrocytes from neonatal versus adult animals).



2002; Matias *et al.* 2023), astrocytes from neonatal animals aged *in vitro* showed an increased glutamate uptake, which could represent a neuroprotective mechanism of astrocytes against excitotoxicity. However, in astrocytes obtained from adult animals, *in vitro* aging decreased glutamate uptake. Interestingly, mice transcriptome datasets show that GLT-1 expression increased from 1 to 9 old of age but drastically decreased in the astrocytes of 2-old animals (Matias *et al.* 2023). Therefore, glutamate uptake function in astrocytes seems to vary dependent on the stage of aging and considering the marked downregulation of GLAST and GLT-1 found in astrocytes obtained from adult animals aged *in vitro*, these cells may reproduce the glutamatergic alterations that occur in advanced ages and that increased the susceptibility to excitotoxicity.

Glutamate uptake can be also modulated by redistribution of glutamate transporters to or from the plasma membrane, which is under regulation of many signaling pathways (Robinson 2006). We found that the changes in glutamate uptake activity induced by *in vitro* aging model in astrocytes isolated from neonatal and adult animals were dependent on different signaling pathways. While the inhibition of PI3K prevented the increase of glutamate uptake in astrocytes from neonates, the inhibition of p38 MAPK prevented the impairment of glutamate uptake in astrocytes from adults. PI3K signaling may lead to changes in glial cell functions, and it was already demonstrated that PI3K modulates GLT-1 mRNA levels (Peng *et al.* 2019) and protein content in cell surface (Guillet *et al.* 2005). In contrast, p38 MAPK plays a key role in pathological processes and has been associated with downregulation of GLT-1 (Zhang *et al.* 2019) and GLAST (Piao *et al.* 2015). Noteworthy, both glutamate transporters and p38 MAPK are redox-sensitive (Trotti *et al.* 1998; Vaziri and Rodríguez-Iturbe 2006), thus an increased ROS production may be linked to the glutamate uptake impairment. In line with this, astrocytes exposed to H₂O₂ show a decreased glutamate uptake, which was potentiated under an *in vitro* aging condition (Pertusa *et al.* 2007). Thus, it seems likely that *in vitro* aging activates signaling pathways depending on cellular context, which may result in differential effects on glutamate transporter regulation.

GS is a key enzyme that catalyzes the conversion of glutamate into glutamine in astrocytes. The glutamate-glutamine cycle is essential for the replenishment of presynaptic glutamate and physiological synaptic activity, while its impairment is also associated with glutamate excitotoxicity (Jayakumar and Norenberg 2016; Cheung *et al.* 2022). *In vitro* senescence models have demonstrated both upregulation and downregulation of GS in astrocytes (Shen *et al.* 2014; Cao *et al.* 2019; Matias *et al.* 2023). In the current study, we observed that *in vitro* aging did not change GS activity in astrocytes from neonatal rats, although there was an increase in glutamate uptake. In astrocytes from adult

animals, accompanying the impairment in glutamate uptake, *in vitro* aging caused a decrease in GS activity. However, there was no difference in GS mRNA expression comparing astrocytes aged *in vitro* derived from neonatal and adult rats. This result suggests that the decreased activity may be a consequence of oxidative stress (Frieg *et al.* 2021). Moreover, in accordance with our previous data (Bellaver *et al.* 2017; Santos *et al.* 2018; Bobermin *et al.* 2020), astrocytes from adult animals showed a reduction of GS at basal conditions, reinforcing age-related changes in its functioning.

Redox imbalance and oxidative stress are hallmarks of brain aging (Mattson and Arumugam 2018). Although astrocytes notably participate in antioxidant defenses, they may also be an important source of ROS in injury conditions (Rizor *et al.* 2019). *In vitro* aging increased ROS production in astrocytes from both neonatal and adult rats, as well as an age-related difference was observed at basal conditions. The challenge with H₂O₂ further increased ROS production only in astrocytes from adult rats aged *in vitro*, suggesting a higher sensitivity of these cells to oxidative stimuli. In contrast, the well-known antioxidant resveratrol was able to decrease ROS production in astrocytes aged *in vitro* derived from both neonatal and adult animals in a manner dependent on HO-1, thus supporting its already demonstrated glioprotective effects during aging (Bobermin *et al.* 2022; Sovrani *et al.* 2023). Nrf2/HO-1 signaling has been proposed as an important mechanism underlying the protective roles of resveratrol and to prevent age-related oxidative stress (Bobermin *et al.* 2019, 2022; Liu *et al.* 2021; Zhao *et al.* 2021). Of note, the gene expression of Nrf2 and HO-1 was decreased in astrocytes aged *in vitro* from adult rats compared to astrocytes aged *in vitro* from neonatal rats, which may explain at least in part the increased susceptibility to the oxidative stimulus with H₂O₂. In addition, intracellular levels of GSH and the activity of GCL, the limiting enzyme of GSH biosynthesis, were decreased only in astrocytes aged *in vitro* from adult animals. It has been reported that the levels of GSH in astrocytes and in brain tissue decline with age, being potentially associated with neurodegenerative disorders (Lee *et al.* 2010; Currais and Maher 2013; Bellaver *et al.* 2017). Moreover, although we found that *in vitro* aging increased GPx activity in astrocytes from adult rats, possibly as a compensatory effect, it seems to be insufficient to counteract H₂O₂-induced ROS production.

Inflammatory response is another hallmark of aging, as well as a key element in the pathogenesis of neurodegenerative diseases (López-Otín *et al.* 2013; Ransohoff 2016). Astrocytes have been pointed as a significant source of the pro-inflammatory mediators, including TNF- α , IL-1 β , and IL-6, involved in neuro-inflammation (López-Teros *et al.* 2022). Here, we confirm that *in vitro* aging can induce the characteristic pro-inflammatory profile in astrocytes, particularly regarding to TNF- α and IL-1 β release, obtained

from both neonatal and adult animals. These data are in line with our previous study in astrocytes obtained from 1 old animals (Bobermin *et al.* 2022). On the other hand, resveratrol mediated an anti-inflammatory effect via HO-1 only in astrocytes from adult rats, which is also consistent with our previous findings (Bobermin *et al.* 2022; Sovrani *et al.* 2023). Of note, inflammatory response upon LPS stimulation seems to be exacerbated in aged astrocytes (Clarke *et al.* 2018; Bobermin *et al.* 2022). Interestingly, we observed that incubation with LPS potentiated cytokine release particularly in *in vitro* aged astrocytes obtained from adult animals via TLR4 receptor, whose expression has been also correlated with age (Letiembre *et al.* 2007). Thus, considering that aging affects the ability of astrocytes to respond to acute inflammatory stimuli and can sensitize the brain to infections or stress (Sparkman and Johnson 2008; Bobermin *et al.* 2022; Quincozes-Santos *et al.* 2023), *in vitro* cellular models are essential for studying alterations in inflammatory responses of astrocytes with aging.

Therefore, there are obvious differential effects of *in vitro* aging in astrocytes from neonatal and adult rats. Based on these results, another set of experiments regarding to gene expression was performed to investigate potential molecular mechanisms associated with such differences, i.e., the specific features of *in vitro* aged astrocytes from adult rats that distinguish them from *in vitro* aged astrocytes from neonatal rats. Compared to astrocytes from neonates, astrocytes from adult animals aged *in vitro* show upregulation of inflammatory-related genes (TNF- α , IL-1 β , p65 NF κ B, iNOS, COX-2), in addition to the senescence marker p21. The expression of AQP4 was also upregulated in astrocytes from adult rats, and this water channel has been implicated in neuroinflammation and neurodegenerative diseases (Valenza *et al.* 2020). Additionally, astrocytes derived from adult animals aged *in vitro* had a decreased release of the anti-inflammatory cytokine IL-10 and the trophic factor GDNF, which may compromise their supportive functions (Lawrence *et al.* 2023). We also observed a marked decrease of GFAP mRNA levels in astrocytes from adult rats aged *in vitro*, in agreement with our previous studies that showed an age-dependent decrease of GFAP content in astrocyte cultures (Souza *et al.* 2015; Bellaver *et al.* 2017). The expression of vimentin and nestin, which decreases with age as they are progressively replaced by GFAP, was also downregulated in astrocytes aged *in vitro*. Although an increase of GFAP has been found in aging (Salas *et al.* 2020), a decrease of GFAP expression has been detected at the early stages of age-related neurodegenerative diseases (Rodríguez *et al.* 2014; Rodríguez-Arellano *et al.* 2016). Thus, it is important to consider that other cellular alterations may precede the GFAP upregulation. Furthermore, the profile of GFAP expression in astrocyte culture is not a consensus (Orre *et al.* 2014; Rodríguez-Arellano *et al.*

2016; Bellaver *et al.* 2017) and it is not an absolute marker of reactivity, since basal expression of GFAP is variable depending on the brain region and there are discrepancies between mRNA and protein levels (Escartin *et al.* 2021).

Emerging evidence has supported that astrocytes can be functionally heterogeneous (Matias *et al.* 2019). Although the nomenclature A1 and A2 for reactive astrocytes is dichotomic and may not represent the diversity of phenotypes that these cells can assume depending on age and or in response to pathologic conditions, A1 phenotype has been related to neurotoxic roles while A2 has neuroprotective properties. In this regard, A1-like astrocytes show upregulation of pro-inflammatory mediators (IL-1 β , TNF- α , and IL-6) and NF κ B, inhibition of PI3K-Akt pathway, downregulation of GDNF and other trophic factors, and changes in the expression of AQP4, among other hallmarks (Lawrence *et al.* 2023). Therefore, our data from *in vitro* aged astrocytes, particularly those obtained from mature animals, are consistent with an induction of A1-like astrocyte reactivity, which in turn is associated with a loss of supportive roles.

Changes in astrocyte functions associated with aging process and their impacts on vulnerability of brain to specific diseases and cognitive decline are only beginning to be understood. Despite of the complexity of aging process, cell culture remains a valuable tool for elucidating its underlying mechanisms. Here, we confirm age-related changes in astrocyte functions, comparing cells obtained from neonatal and adult rats, which can impact the experimental limitations in long-term maintenance of the animals to perform cellular and molecular studies about aging. In addition, we showed that *in vitro* aging can produce different effects in astrocyte cultures obtained from neonatal and adult Wistar rats, as well as differential responses to oxidative, inflammatory, and protective stimuli. In summary, primary astrocyte cultures obtained from adult animals and further aged *in vitro* may better reproduce glial changes and represent an innovative tool to study astrocyte aging, as well as potential glioprotective and/or anti-aging strategies.

Acknowledgements This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Universidade Federal do Rio Grande do Sul and Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção (INCTEN/CNPq).

Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest The authors declare no conflict of interest.

References

- Bellaver B, Souza DG, Bobermin LD *et al* (2015) Resveratrol protects hippocampal astrocytes against LPS-induced neurotoxicity through HO-1, p38 and ERK pathways. *Neurochem Res* 40:1600–1608. <https://doi.org/10.1007/s11064-015-1636-8>
- Bellaver B, Souza DG, Souza DO, Quincozes-Santos A (2017) Hippocampal astrocyte cultures from adult and aged rats reproduce changes in glial functionality observed in the aging brain. *Mol Neurobiol* 54:2969–2985. <https://doi.org/10.1007/s12035-016-9880-8>
- Bobermin LD, de Souza Almeida RR, Weber FB *et al* (2022) Lipopolysaccharide induces gliotoxicity in hippocampal astrocytes from aged rats: insights about the glioprotective roles of resveratrol. *Mol Neurobiol*. <https://doi.org/10.1007/s12035-021-02664-8>
- Bobermin LD, Roppa RHA, Gonçalves C-A, Quincozes-Santos A (2020) Ammonia-induced glial-inflammation. *Mol Neurobiol* 57:3552–3567. <https://doi.org/10.1007/s12035-020-01985-4>
- Bobermin LD, Roppa RHA, Quincozes-Santos A (2019) Adenosine receptors as a new target for resveratrol-mediated glioprotection. *Biochim Biophys Acta Mol Basis Dis* 1865:634–647. <https://doi.org/10.1016/j.bbadis.2019.01.004>
- Browne RW, Armstrong D (1998) Reduced glutathione and glutathione disulfide. In: Free radical and antioxidant protocols. Humana Press, New Jersey, pp 347–352. <https://doi.org/10.1385/0-89603-472-0:347>
- Cao P, Zhang J, Huang Y *et al* (2019) The age-related changes and differences in energy metabolism and glutamate-glutamine recycling in the d-gal-induced and naturally occurring senescent astrocytes *in vitro*. *Exp Gerontol* 118:9–18. <https://doi.org/10.1016/j.exger.2018.12.018>
- Chen Z, Yuan Z, Yang S *et al* (2023) Brain Energy metabolism: astrocytes in neurodegenerative diseases. *CNS Neurosci Ther* 29:24–36. <https://doi.org/10.1111/cns.13982>
- Cheung G, Bataveljic D, Visser J *et al* (2022) Physiological synaptic activity and recognition memory require astroglial glutamine. *Nat Commun* 13:753. <https://doi.org/10.1038/s41467-022-28331-7>
- Clarke LE, Liddelow SA, Chakraborty C *et al* (2018) Normal aging induces A1-like astrocyte reactivity. *Proc Natl Acad Sci USA* 115:E1896–E1905. <https://doi.org/10.1073/pnas.1800165115>
- Cunnane SC, Trushina E, Morland C *et al* (2020) Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. *Nat Rev Drug Discov* 19:609–633. <https://doi.org/10.1038/s41573-020-0072-x>
- Currais A, Maher P (2013) Functional consequences of age-dependent changes in glutathione status in the brain. *Antioxid Redox Signal* 19:813–822. <https://doi.org/10.1089/ars.2012.4996>
- Danbolt NC (2001) Glutamate uptake. *Prog Neurobiol* 65:1–105. [https://doi.org/10.1016/S0301-0082\(00\)00067-8](https://doi.org/10.1016/S0301-0082(00)00067-8)
- dos Santos AQ, Nardin P, Funchal C *et al* (2006) Resveratrol increases glutamate uptake and glutamine synthetase activity in C6 glioma cells. *Arch Biochem Biophys* 453:161–167. <https://doi.org/10.1016/j.abb.2006.06.025>
- Escartin C, Galea E, Lakatos A *et al* (2021) Reactive astrocyte nomenclature, definitions, and future directions. *Nat Neurosci* 24:312–325. <https://doi.org/10.1038/s41593-020-00783-4>
- Franceschi C, Garagnani P, Parini P *et al* (2018) Inflammation: a new immune–metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* 14:576–590. <https://doi.org/10.1038/s41574-018-0059-4>
- Frieg B, Görg B, Gohlke H, Häussinger D (2021) Glutamine synthetase as a central element in hepatic glutamine and ammonia metabolism: novel aspects. *Biol Chem* 402:1063–1072. <https://doi.org/10.1515/hsz-2021-0166>
- Gonçalves C-A, Rodrigues L, Bobermin LD *et al* (2018) Glycolysis-derived compounds from astrocytes that modulate synaptic communication. *Front Neurosci* 12:1035. <https://doi.org/10.3389/fnins.2018.01035>
- Gottfried C, Tramontina F, Gonçalves D *et al* (2002) Glutamate uptake in cultured astrocytes depends on age: a study about the effect of guanosine and the sensitivity to oxidative stress induced by H₂O₂. *Mech Ageing Dev* 123:1333–1340. [https://doi.org/10.1016/S0047-6374\(02\)00069-6](https://doi.org/10.1016/S0047-6374(02)00069-6)
- Guerrero A, De Strooper B, Arancibia-Cárcamo IL (2021) Cellular senescence at the crossroads of inflammation and Alzheimer's disease. *Trends Neurosci* 44:714–727. <https://doi.org/10.1016/j.tins.2021.06.007>
- Guillet B, Velly L, Canolle B *et al* (2005) Differential regulation by protein kinases of activity and cell surface expression of glutamate transporters in neuron-enriched cultures. *Neurochem Int* 46:337–346. <https://doi.org/10.1016/j.neuint.2004.10.006>
- Jayakumar AR, Norenberg MD (2016) Glutamine synthetase: role in neurological disorders. *Adv Neurobiol* 13:327–350. https://doi.org/10.1007/978-3-319-45096-4_13
- Kleinkauf-Rocha J, Bobermin LD, de Mattos Machado P *et al* (2013) Lipic acid increases glutamate uptake, glutamine synthetase activity and glutathione content in C6 astrocyte cell line. *Int J Dev Neurosci* 31:165–170. <https://doi.org/10.1016/j.ijdevneu.2012.12.006>
- Lau V, Ramer L, Tremblay M-È (2023) An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer's disease. *Nat Commun* 14:1670. <https://doi.org/10.1038/s41467-023-37304-3>
- Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR (2023) Roles of neuropathology-associated reactive astrocytes: a systematic review. *Acta Neuropathol Commun* 11:42. <https://doi.org/10.1186/s40478-023-01526-9>
- Lee M, Cho T, Jantarototai N *et al* (2010) Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. *FASEB J* 24:2533–2545. <https://doi.org/10.1096/fj.09-149997>
- Leite Santos C, Vizuete AFK, Weber FB *et al* (2023) Age-dependent effects of resveratrol in hypothalamic astrocyte cultures. *NeuroReport* 34:419–425. <https://doi.org/10.1097/WNR.0000000000001906>
- Letiembre M, Hao W, Liu Y *et al* (2007) Innate immune receptor expression in normal brain aging. *Neuroscience* 146:248–254. <https://doi.org/10.1016/j.neuroscience.2007.01.004>
- Limbac C, Oron TR, Alimirah F *et al* (2020) Astrocyte senescence promotes glutamate toxicity in cortical neurons. *PLoS ONE* 15:e0227887. <https://doi.org/10.1371/journal.pone.0227887>
- Liu X-L, Zhao Y-C, Zhu H-Y *et al* (2021) Taxifolin retards the D-galactose-induced aging process through inhibiting Nrf2-mediated oxidative stress and regulating the gut microbiota in mice. *Food Funct* 12:12142–12158. <https://doi.org/10.1039/D1FO01349A>
- Liu Y, Shen X, Zhang Y *et al* (2023) Interactions of glial cells with neuronal synapses, from astrocytes to microglia and oligodendrocyte lineage cells. *Glia* 71:1383–1401. <https://doi.org/10.1002/glia.24343>
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402–408. <https://doi.org/10.1006/meth.2001.1262>
- López-Otín C, Blasco MA, Partridge L *et al* (2013) The hallmarks of aging. *Cell* 153:1194–1217. <https://doi.org/10.1016/j.cell.2013.05.039>
- López-Teros M, Alarcón-Aguilar A, López-Diazguerrero NE *et al* (2022) Contribution of senescent and reactive astrocytes on central nervous system inflammation. *Biogerontology* 23:21–33. <https://doi.org/10.1007/s10522-022-09952-3>
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* 193:265–275
- Matias I, Diniz LP, Araujo APB *et al* (2023) Age-associated upregulation of glutamate transporters and glutamine synthetase in senescent astrocytes *in vitro* and in the mouse and human hippocampus. *ASN Neuro* 15:175909142311579. <https://doi.org/10.1177/17590914231157974>
- Matias I, Diniz LP, Damico IV, *et al* (2022) Loss of lamin-B1 and defective nuclear morphology are hallmarks of astrocyte

- senescence *in vitro* and in the aging human hippocampus. *Aging Cell* 21. <https://doi.org/10.1111/accel.13521>
- Matias I, Morgado J, Gomes FCA (2019) Astrocyte Heterogeneity: Impact to Brain Aging and Disease. *Front Aging Neurosci* 11:59. <https://doi.org/10.3389/fnagi.2019.00059>
- Mattson MP, Arumugam TV (2018) Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. *Cell Metab* 27:1176–1199. <https://doi.org/10.1016/j.cmet.2018.05.011>
- Orre M, Kamphuis W, Osborn LM *et al* (2014) Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. *Neurobiol Aging* 35:1–14. <https://doi.org/10.1016/j.neurobiolaging.2013.07.008>
- Palmer AL, Ousman SS (2018) Astrocytes and aging. *Front Aging Neurosci* 10:337. <https://doi.org/10.3389/fnagi.2018.00337>
- Peng M, Ling X, Song R *et al* (2019) Upregulation of GLT-1 via PI3K/Akt Pathway Contributes to Neuroprotection Induced by Dexmedetomidine. *Front Neurol* 10:1041. <https://doi.org/10.3389/fneur.2019.01041>
- Pertusa M, García-Matas S, Rodríguez-Farré E *et al* (2007) Astrocytes aged *in vitro* show a decreased neuroprotective capacity: reduced neuroprotection by aged astrocytes. *J Neurochem* 101:794–805. <https://doi.org/10.1111/j.1471-4159.2006.04369.x>
- Piao C, Ranaivo HR, Rusie A *et al* (2015) Thrombin decreases expression of the glutamate transporter GLAST and inhibits glutamate uptake in primary cortical astrocytes via the Rho kinase pathway. *Exp Neurol* 273:288–300. <https://doi.org/10.1016/j.expneurol.2015.09.009>
- Potier B, Billard J-M, Rivière S *et al* (2010) Reduction in glutamate uptake is associated with extrasynaptic NMDA and metabotropic glutamate receptor activation at the hippocampal CA1 synapse of aged rats: synaptic effects of reduced glutamate uptake in the aged rat hippocampus. *Aging Cell* 9:722–735. <https://doi.org/10.1111/j.1474-9726.2010.00593.x>
- Quincozes-Santos A, Bobermin LD, Costa NLF, *et al* (2023) The role of glial cells in Zika virus-induced neurodegeneration. *Glia*. <https://doi.org/10.1002/glia.24353>. [glia.24353](https://doi.org/10.1002/glia.24353)
- Quincozes-Santos A, Bobermin LD, de Souza DG *et al* (2013) Gliopreventive effects of guanosine against glucose deprivation *in vitro*. *Purinergic Signalling* 9:643–654. <https://doi.org/10.1007/s11302-013-9377-0>
- Quincozes-Santos A, Bobermin LD, Souza DG *et al* (2014) Guanosine protects C6 astroglial cells against azide-induced oxidative damage: a putative role of heme oxygenase 1. *J Neurochem* 130:61–74. <https://doi.org/10.1111/jnc.12694>
- Quincozes-Santos A, Santos CL, de Souza Almeida RR *et al* (2021) Gliotoxicity and Glioprotection: the Dual Role of Glial Cells. *Mol Neurobiol* 58:6577–6592. <https://doi.org/10.1007/s12035-021-02574-9>
- Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. *Science* 353:777–783. <https://doi.org/10.1126/science.aag2590>
- Rizor A, Pajarillo E, Johnson J *et al* (2019) Astrocytic Oxidative/Nitrosative Stress Contributes to Parkinson's Disease Pathogenesis: The Dual Role of Reactive Astrocytes. *Antioxidants* 8:265. <https://doi.org/10.3390/antiox8080265>
- Robinson MB (2006) Acute regulation of sodium-dependent glutamate transporters: a focus on constitutive and regulated trafficking. In: Sitte HH, Freissmuth M (eds) *Neurotransmitter transporters*. Springer-Verlag, Berlin/Heidelberg, pp 251–275
- Rodríguez JJ, Yeh C-Y, Terzieva S *et al* (2014) Complex and region-specific changes in astroglial markers in the aging brain. *Neurobiol Aging* 35:15–23. <https://doi.org/10.1016/j.neurobiolaging.2013.07.002>
- Rodríguez-Arellano JJ, Párpura V, Zorec R, Verkhratsky A (2016) Astrocytes in physiological aging and Alzheimer's disease. *Neuroscience* 323:170–182. <https://doi.org/10.1016/j.neuroscience.2015.01.007>
- Rosa PM, Martins LAM, Souza DO, Quincozes-Santos A (2018) Glioprotective Effect of Resveratrol: an Emerging Therapeutic Role for Oligodendroglial Cells. *Mol Neurobiol* 55:2967–2978. <https://doi.org/10.1007/s12035-017-0510-x>
- Salas IH, Burgado J, Allen NJ (2020) Glia: victims or villains of the aging brain? *Neurobiol Dis* 143:105008. <https://doi.org/10.1016/j.nbd.2020.105008>
- Santos CL, Roppa PHA, Truccolo P *et al* (2018) Age-dependent neurochemical remodeling of hypothalamic astrocytes. *Mol Neurobiol* 55:5565–5579. <https://doi.org/10.1007/s12035-017-0786-x>
- Seelig GF, Meister A (1985) Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. *Methods Enzymol* 113:379–390. [https://doi.org/10.1016/s0076-6879\(85\)13050-8](https://doi.org/10.1016/s0076-6879(85)13050-8)
- Shen Y, Gao H, Shi X *et al* (2014) Glutamine synthetase plays a role in d-galactose-induced astrocyte aging *in vitro* and *in vivo*. *Exp Gerontol* 58:166–173. <https://doi.org/10.1016/j.exger.2014.08.006>
- Soreq L, Rose J, Soreq E *et al* (2017) Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. *Cell Rep* 18:557–570. <https://doi.org/10.1016/j.celrep.2016.12.011>
- Souza DG, Bellaver B, Raupp GS *et al* (2015) Astrocytes from adult Wistar rats aged *in vitro* show changes in glial functions. *Neurochem Int* 90:93–97. <https://doi.org/10.1016/j.neuint.2015.07.016>
- Souza DG, Bellaver B, Souza DO, Quincozes-Santos A (2013) Characterization of adult rat astrocyte cultures. *PLoS ONE* 8:e60282. <https://doi.org/10.1371/journal.pone.0060282>
- Sovrani V, Bobermin LD, Santos CL *et al* (2023) Effects of long-term resveratrol treatment in hypothalamic astrocyte cultures from aged rats. *Mol Cell Biochem* 478:1205–1216. <https://doi.org/10.1007/s11010-022-04585-z>
- Sparkman NL, Johnson RW (2008) neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. *Neuro-ImmunoModulation* 15:323–330. <https://doi.org/10.1159/000156474>
- Trotti D, Danbolt NC, Volterra A (1998) Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? *Trends Pharmacol Sci* 19:328–334. [https://doi.org/10.1016/S0165-6147\(98\)01230-9](https://doi.org/10.1016/S0165-6147(98)01230-9)
- Valenza M, Facchinetti R, Steardo L, Scuderi C (2020) Altered waste disposal system in aging and alzheimer's disease: focus on astrocytic Aquaporin-4. *Front Pharmacol* 10:1656. <https://doi.org/10.3389/fphar.2019.01656>
- Vaziri ND, Rodríguez-Iturbe B (2006) Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. *Nat Rev Nephrol* 2:582–593. <https://doi.org/10.1038/ncpneph0283>
- Verkhratsky A, Nedergaard M (2018) Physiology of astroglia. *Physiol Rev* 98:239–389. <https://doi.org/10.1152/physrev.00042.2016>
- Yanai S, Endo S (2021) Functional aging in male C57BL/6J mice across the life-span: a systematic behavioral analysis of motor, emotional, and memory function to define an aging phenotype. *Front Aging Neurosci* 13:697621. <https://doi.org/10.3389/fnagi.2021.697621>
- Zhang L-Y, Hu Y-Y, Zhao C-C *et al* (2019) The mechanism of GLT-1 mediating cerebral ischemic injury depends on the activation of p38 MAPK. *Brain Res Bull* 147:1–13. <https://doi.org/10.1016/j.brainresbull.2019.01.028>
- Zhang S, Lachance BB, Mattson MP, Jia X (2021) Glucose metabolic crosstalk and regulation in brain function and diseases. *Prog Neurobiol* 204:102089. <https://doi.org/10.1016/j.pneurobio.2021.102089>
- Zhao Y, Liu X, Zheng Y *et al* (2021) Aronia melanocarpa polysaccharide ameliorates inflammation and aging in mice by modulating the AMPK/SIRT1/NF-κB signaling pathway and gut microbiota. *Sci Rep* 11:20558. <https://doi.org/10.1038/s41598-021-00071-6>

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.